Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

  • Quirant, Bibiana|||0000-0002-3875-8074
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases by restoring homeostasis and targeting specifically autoreactive responses. Here, we explore the hypothesis that systemic inflammation occurring in autoimmune diseases, such as multiple sclerosis (MS), can generate a disease-specific environment able to alter the functionality of tolDC. In this context in fact, a combined therapy of tolDC with an immunomodulatory treatment could potentiate the beneficial effect of this antigen-specific cell therapy. For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS. VitD3-tolDC were generated from healthy donors and MS patients and co-cultured with allogeneic peripheral blood mononuclear cells, in the presence or absence of IFN-beta. In vitro, VitD3-tolDC treatment reduced the percentage of activated T cells and allogeneic proliferation, whereas VitD3-tolDC+IFN-beta treatment enhanced the suppressive ability of VitD3-tolDC and, additionally, induced a shift towards a Th2 profile. To determine the clinical benefit of the combined therapy, C57BL/6-experimental autoimmune encephalomyelitis (EAE)-induced mice were treated with antigen-specific VitD3-tolDC and/or IFN-beta. Treatment of EAE mice with combined therapy ameliorated the disease course compared to each monotherapy. These results suggest that a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta may represent a promising strategy for MS patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ways forward for tolerance-inducing cellular therapies- An afactt perspective

  • Ten Brinke, Anja
  • Martinez-Llordella, Marc
  • Cools, Nathalie|||0000-0002-0459-901X
  • Hilkens, Catharien M. U.
  • van Ham, S. Marieke
  • Sawitzki, Birgit
  • Geissler, Edward K.
  • Lombardi, Giovanna
  • Trzonkowski, Piotr
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

  • Quirant, Bibiana|||0000-0002-3875-8074
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Hervas-Garcia, Jose Vicente|||0000-0002-1132-0291
  • Brieva Ruiz, Luis|||0000-0002-5871-6189
  • Moral-Torres, Ester
  • Cano, Antonio
  • Munteis, Elvira|||0000-0002-6195-9106
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1 cells (relapsed: 11 60 ± 4 17%vs. nonrelapsed: 9 25 ± 3 17%, p < 0 05) and Th1Th17 cells (relapsed: 15 65 ± 6 15%vs. nonrelapsed: 10 14 ± 4 05%, p < 0 01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17 (CD4CCR7CD45RACCR6CXCR3) cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ardiaca-Martínez, Alicia
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ten Brinke, Anja
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe

  • Oras, A.
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Popadic, D.
  • Thunberg, S.
  • Winqvist, O.
  • Heck, S.
  • Cwikowski, M.
  • Riemann, D.
  • Seliger, B.
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Uibo, R.|||0000-0002-2298-1300
  • Giese, Thomas|||0000-0002-9649-0424
A group of European FOCIS Centers of Excellence adapted panels of the Human Immunophenotyping Consortium (HIPC) for whole blood analysis. Using four core panels [T/regulatory T cell/B/natural killer (T/Treg/B/NK) and myeloid cells] the main leukocyte populations were analyzed in a clinical-diagnostic setting in a harmonized manner across different platforms. As a first step, the consortium presents here the absolute and relative frequencies of the leukocyte subpopulations in the peripheral blood of more than 300 healthy volunteers across six different European centers.